By
Treatment mixing Tecentriq with Avastin and chemotherapies carboplatin and paclitaxel boosted overall survival in first-line treatment, compared to patients who received Avastin plus carboplatin and paclitaxel. Roche said it would submit the data to authorities and hopes for a quick approval.